SCHEMBL3135280

SCHEMBL3135280

CN1CCN(c2cc(-c3cccc(S(=O)(=O)n4ccc(/C=C/C(=O)NOC5CCCCO5)c4)c3)ccn2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 9/20 0.39
▸ HDAC2 Q92769 8/20 0.39
▸ HDAC6 Q9UBN7 8/20 0.39
▸ HDAC3 O15379 7/20 0.39
▸ HDAC10 Q969S8 7/20 0.39
▸ HDAC11 Q96DB2 7/20 0.39
▸ HDAC9 Q9UKV0 7/20 0.39
▸ HDAC4 P56524 6/20 0.39
▸ HDAC7 Q8WUI4 6/20 0.39
▸ HDAC8 Q9BY41 6/20 0.39
▸ HDAC5 Q9UQL6 6/20 0.39
▸ RXRA P19793 1/20 0.38
▸ KDM1A O60341 1/20 0.36
▸ MTOR P42345 1/20 0.36
▸ SMG1 Q96Q15 1/20 0.36
▸ TGFBR1 P36897 1/20 0.36
▸ PIM2 Q9P1W9 4/20 0.35
▸ PIM1 P11309 2/20 0.34
▸ CSNK2A2 P19784 1/20 0.34
▸ CSNK2A1 P68400 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3135287 1.00 HDAC1 (0.39) HDAC1HDAC2HDAC6HDAC3HDAC10
SCHEMBL3133844 0.93 HDAC1 (0.42) HDAC1HDAC2HDAC6HDAC3HDAC10
SCHEMBL3133829 0.93 HDAC1 (0.42) HDAC1HDAC2HDAC6HDAC3HDAC10
SCHEMBL3419807 0.90 HDAC1 (0.37) HDAC1HDAC2HDAC6HDAC3HDAC10
SCHEMBL3145249 0.90 HDAC1 (0.37) HDAC1HDAC2HDAC6HDAC3HDAC10
SCHEMBL3420405 0.88 HDAC1 (0.38) HDAC1HDAC2HDAC6HDAC3HDAC10
SCHEMBL3420403 0.88 HDAC1 (0.38) HDAC1HDAC2HDAC6HDAC3HDAC10
SCHEMBL3133861 0.87 RXRA (0.35) HDAC1HDAC2HDAC6HDAC3HDAC10
SCHEMBL3133867 0.87 RXRA (0.35) HDAC1HDAC2HDAC6HDAC3HDAC10
SCHEMBL3140294 0.85 HDAC1 (0.51) HDAC1HDAC2HDAC6HDAC3HDAC10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815855-B2 N-sulphonylpyrroles and their use as histone deacetylase inhibitors 4SC AG (DE) 2014-08-26 — — US disclosed
US-20100074862-A1 N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS MAIER THOMAS 2010-03-25 — — US disclosed
US-7666868-B2 e.g. N-Hydroxy-3-{1-[4-(1-methyl-1H-indol-5-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide; antiproliferative, anticarcinogenic, antiinflammatory, neuroleptic agent, autoimmune disorders 4SC AG (DE) 2010-02-23 — — US disclosed
EP-1861365-B1 N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS 4SC AG (DE) 2009-07-01 — — EP disclosed
US-20080176848-A1 e.g. N-Hydroxy-3-{1-[4-(1-methyl-1H-indol-5-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide; antiproliferative, anticarcinogenic, antiinflammatory, neuroleptic agent, autoimmune disorders NYCOMED GMBH (DE) 2008-07-24 — — US disclosed
EP-1861365-A1 N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS Nycomed GmbH (DE) 2007-12-05 — — EP disclosed
WO-2006097474-A1 N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS NYCOMED GMBH (DE) 2006-09-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176848-A1 e.g. N-Hydroxy-3-{1-[4-(1-methyl-1H-indol-5-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide; antiproliferative, anticarcinogenic, antiinflammatory, neuroleptic agent, autoimmune disorders HDAC1, H1-3, HDAC2 HDAC1 1/4885HDAC2 3/4885HDAC6 17/4885
US-20100074862-A1 N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS HDAC1, HDAC3, HDAC2 HDAC1 1/4885HDAC2 3/4885HDAC6 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback